---
title: 'Health-related quality of life and symptoms of chronic myeloid leukemia patients
  after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial'
date: '2024-07-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38987274/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240711181556&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Limited data is available on the health-related quality of life (HRQoL)
  and symptoms of patients with chronic myeloid leukemia (CML) who are in treatment-free
  remission (TFR). We herein report HRQoL results from the EURO-SKI trial. Patients
  who had been on tyrosine kinase inhibitors (TKIs) therapy for at least 3 years and
  achieved MR4 for at least 1 year were enrolled from 11 European countries, and the
  EORTC QLQ-C30 and the FACIT-Fatigue questionnaires were used to assess HRQoL and
  ...
disable_comments: true
---
Limited data is available on the health-related quality of life (HRQoL) and symptoms of patients with chronic myeloid leukemia (CML) who are in treatment-free remission (TFR). We herein report HRQoL results from the EURO-SKI trial. Patients who had been on tyrosine kinase inhibitors (TKIs) therapy for at least 3 years and achieved MR4 for at least 1 year were enrolled from 11 European countries, and the EORTC QLQ-C30 and the FACIT-Fatigue questionnaires were used to assess HRQoL and ...